Home > News & Media > GSK to provide malaria vaccines for Gavi eligible countries
GSK to provide malaria vaccines for Gavi eligible countries
December 6, 2021
GlaxoSmithKline (GSK) has welcomed the decision of the Gavi Board to provide funding for the development and introduction of malaria vaccines into routine child immunisation programmes in Gavi eligible countries.
The new development will give a vital tool to healthcare providers to address the steep rise of malaria cases in children living in Africa.
This follows the World Health Organisation’s (WHO) recommendation for the broader use of GSK’s RTS,S/AS01e to combat the issue of childhood illness and deaths from malaria in children living in sub-Saharan Africa and other regions with moderate to high transmission, as defined by WHO.
Africa continues to have the heaviest malaria burden and African children are at highest risk of dying of malaria.
Over 260,000 African children under the age of five died from malaria in 2019 and COVID-19 has only exacerbated this disease burden. This highlights the ever-growing, urgent need for new and innovative tools to combat malaria.
RTS,S/AS01e is the result of over 35 years of research led by GSK, with non-profit health organisation PATH and other partners.
It is the first and only malaria vaccine to have been shown in pivotal long-term clinical trials to significantly reduce malaria in children.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.